Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pentadecane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.62 |
| ▸ | FDPS | P14324 | 12/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL2999123 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Phosphoric Acid SCHEMBL3004733 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Nonane SCHEMBL2999229 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Phosphoric Acid SCHEMBL3005198 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Decane SCHEMBL3004955 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Phosphoric Acid SCHEMBL2995237 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Tridecane SCHEMBL3004141 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Phosphoric Acid SCHEMBL3005549 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Heptane SCHEMBL3004922 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 | |
| Undecane SCHEMBL2995223 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2FDPSGGPS1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | INNATE PHARMA S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| WO-2010049438-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS FOR THE TREATMENT OF DISEASES | INNATE PHARMA (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | INNATE PHARMA S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2083830-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | Innate Pharma (FR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2040750-A2 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF THERAPEUTIC ANTIBODIES USING GAMMA DELTA T CELL ACTIVATORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008059052-A9 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008146167-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | INNATE PHARMA S.A. (FR) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1948195-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | Innate Pharma (FR) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008059052-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008006895-A2 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF THERAPEUTIC ANTIBODIES USING GAMMA DELTA T CELL ACTIVATORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-01-17 | — | — | WO | disclosed |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | ROMAGNE FRANCOIS | 2007-06-14 | — | — | US | disclosed |
| WO-2007057440-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2007-05-24 | — | — | WO | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| EP-1109818-B1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INST NAT SANTE RECH MED (FR) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | LPAR3 1385/4885LPAR2 1444/4885FDPS 3637/4885 |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | LPAR3 1706/4885LPAR2 1894/4885FDPS 4547/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | LPAR3 571/4885LPAR2 1151/4885FDPS 1119/4885 |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | IL2, IL2RA, CD4 | LPAR3 1798/4885LPAR2 580/4885FDPS 3228/4885 |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | IFNG, IL2, PBK | LPAR3 1462/4885LPAR2 1931/4885FDPS 1558/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | LPAR3 1486/4885LPAR2 1736/4885FDPS 3639/4885 |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | CD4, FCGR3B, IFNG | LPAR3 830/4885LPAR2 982/4885FDPS 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.